Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -83.26% is 203% below its 4-year average of -27.49%, near the low end of its 4-year range (-83.26%–20.17%).
As of the fiscal period ended Wednesday, December 31, 2025. 77.26% below its 12-month average of -46.97%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-83.26%
RETURN ON EQUITY (ROE) AVG TTM
-46.97%
RETURN ON EQUITY (ROE) AVG 3Y
-39.40%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-77.26%
CURRENT VS 3Y AVG
-111.32%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-98.19%
vs the sector median at left
iTonic Holdings Ltd.
Market Cap
$25.57M
Return on Equity (ROE)
-83.26%
TTM Avg
-46.97%
3Y Avg
-39.40%
5Y Avg
N/A
Market Cap
$24.96M
Return on Equity (ROE)
-122.19%
TTM Avg
-88.53%
3Y Avg
-83.45%
5Y Avg
-77.50%
Market Cap
$27.60M
Return on Equity (ROE)
-65.05%
TTM Avg
-525.23%
3Y Avg
-779.21%
5Y Avg
-536.29%
Market Cap
$24.54M
Return on Equity (ROE)
-140.55%
TTM Avg
-62.02%
3Y Avg
-44.98%
5Y Avg
-43.41%
Market Cap
$24.13M
Return on Equity (ROE)
-76.82%
TTM Avg
-235.52%
3Y Avg
-335.24%
5Y Avg
-272.42%
Market Cap
$23.78M
Return on Equity (ROE)
N/A
TTM Avg
-294.82%
3Y Avg
229.70%
5Y Avg
122.55%
Market Cap
$27.86M
Return on Equity (ROE)
-124.64%
TTM Avg
-100.64%
3Y Avg
-80.07%
5Y Avg
-67.08%
Market Cap
$23.53M
Return on Equity (ROE)
-0.80%
TTM Avg
-5.04%
3Y Avg
68.38%
5Y Avg
100.94%
Market Cap
$28.82M
Return on Equity (ROE)
N/A
TTM Avg
78.98%
3Y Avg
134.04%
5Y Avg
114.40%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iTonic Holdings Ltd. (ITOC) | $25.57M | -83.26% | -46.97% | -39.40% | N/A |
| InspireMD, Inc. (NSPR)vs › | $24.96M | -122.19% | -88.53% | -83.45% | -77.50% |
| Seres Therapeutics, Inc. (MCRB)vs › | $27.60M | -65.05% | -525.23% | -779.21% | -536.29% |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.54M | -140.55% | -62.02% | -44.98% | -43.41% |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.13M | -76.82% | -235.52% | -335.24% | -272.42% |
| Kyntra Bio, Inc. (KYNB)vs › | $23.78M | N/A | -294.82% | 229.70% | 122.55% |
| aTyr Pharma, Inc. (ATYR)vs › | $27.86M | -124.64% | -100.64% | -80.07% | -67.08% |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.53M | -0.80% | -5.04% | 68.38% | 100.94% |
| OneMedNet Corporation (ONMD)vs › | $28.82M | N/A | 78.98% | 134.04% | 114.40% |
| Rein Therapeutics Inc. (RNTX)vs › | $23.07M | -487.90% | -205.19% | -102.69% | -68.50% |
ROE
-83.3%
ROA
-56.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -83.26% |
| 2024-12-31 | -10.68% |
| 2023-12-31 | -78.76% |
| 2022-12-31 | 15.10% |
| 2021-12-31 | 20.17% |
